THE APEX TIMES
Abridge CEO Dr. Shiv Rao says new Nvidia and Eli Lilly partnerships aim to advance clinical AI
In an interview on NYSE Live, Abridge’s chief executive described fresh collaboration efforts with Nvidia and Eli Lilly, without laying out terms or technical specifics. The comments underscore the growing push to bring AI copilots into clinical workflows and life-sciences settings.
Abridge CEO Dr. Shiv Rao said the company has launched new partnership discussions involving Nvidia and Eli Lilly, framing the effort as part of a broader push to apply AI to healthcare use cases. Rao made the remarks during an interview tied to NYSE Live, where he discussed how the collaborations could support Abridge’s work delivering AI-generated clinical summaries and other clinician-facing capabilities.
Rao’s comments, as captured in the video listing on Yahoo Finance, focused on “new partnerships” and did not specify the scope of each relationship, the technologies involved, or whether the collaborations are research, commercial deployment, or both. The interview format also means the public disclosure is limited to high-level statements rather than contractual or performance details.
Nvidia’s role in many healthcare AI programs typically relates to the compute layer, including the training and deployment of large AI models on graphics processing units. In life sciences, companies such as Eli Lilly often evaluate AI tools for tasks ranging from clinical documentation to support for research workflows. However, the interview posting does not provide enough detail to determine which parts of these value chains the partners intend to pursue together.
Abridge, for its part, has positioned itself around using AI to assist clinical communication. While the Yahoo Finance listing does not include technical or product specifications in text form, the company’s public identity in the market has centered on transforming unstructured conversations between clinicians and patients into structured outputs that can reduce documentation burden.
The Eli Lilly partnership angle indicates that at least some external stakeholders are exploring AI integration beyond standalone medical documentation tools, potentially aligning with how large pharmaceutical companies think about data capture, evidence generation, and operational efficiency. Still, the interview text does not disclose whether Lilly would use Abridge tools internally, evaluate them in trials, or pursue a broader ecosystem relationship.
Given the limited information made available in the video listing, key commercial and operational questions remain unanswered. The posting does not disclose whether either partnership includes financial terms, exclusivity, named product deployments, or timelines. It also does not clarify the specific AI model approach, governance approach, or how outputs would be validated in clinical contexts.
For the sector, the remarks fit a wider pattern in healthcare AI: hyperscalers and semiconductor suppliers are increasingly partnering with healthcare-focused software vendors, while large pharma firms explore ways to incorporate AI-generated data into real-world operations and long-running research programs. The emphasis on multiple partners also reflects how companies assemble AI stacks across compute, software, and domain workflows.
Why It Matters
- Partnership announcements in healthcare AI can announcement where AI model development and deployment priorities are moving, particularly toward clinician and life-sciences workflows.
- Collaboration with Nvidia suggests an emphasis on the compute and model-serving capabilities needed for large AI systems, though the exact use case is not disclosed.
- Mention of Eli Lilly points to ongoing interest from large pharmaceutical companies in evaluating or integrating AI tools, but the relationship’s nature remains unclear.
- Investors and healthcare stakeholders will likely watch for additional disclosures such as pilot results, governance and validation plans, or measurable deployment milestones.
Sources
Key Facts
- Abridge CEO Dr. Shiv Rao discussed new partnerships involving Nvidia and Eli Lilly during an interview tied to NYSE Live.
- The discussion was published as a Yahoo Finance video listing on June 24, 2026.
- The public-facing text available from the listing describes the partnerships at a high level but does not provide contractual terms.
- No interview text in the listing specifies the exact product features, technical implementations, or deployment timelines tied to the partnerships.
Healthcare Related
Eli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after August
Market commentary tied recent gains in Salior Therapeutics (SLS) and ImmunityBio (IBRX) to a renewed perception that Big Pharma is willing to pay premium prices for immune-focused platforms, pointing to Eli Lilly’s latest reported deal value.
Moderna shares surge 156% in August as investors bet on clinical progress
Moderna’s stock logged its strongest monthly gain in August after market attention concentrated on favorable trial results for one of its pipeline therapies.
Lilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains Early
Eli Lilly says a milestone-based immunology deal that adds a broader scientific platform has begun a Phase 1 study, but its lead medicine is still at the earliest clinical stage, underscoring the execution risk common to early-stage pipeline builds.
Eli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fit
The U.S. drugmaker said it will acquire Merida Biosciences in a transaction valued at $2.88 billion, a move that is drawing attention to how Lilly is expanding its pipeline and capabilities.
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.